Key Highlights

● DSS posted a net loss of about $5.04 million in the June 2026 quarter.

● Quarterly Revenue fell to $3.60 million from $5.29 million a year earlier.

● Cash was $4.07 million at June 30, down from $6.21 million at year-end 2025.

● A Merger with Dr Ashleys awaits regulatory approval, with closing timing uncertain.

DSS, Inc. (NYSE American:DSS) is a diversified Holding Company whose most recent 10-Q, covering the quarter ended June 30, 2026, shows revenue falling and losses continuing. The filing reports a net loss of about $5.04 million for the quarter and includes substantial-doubt language about the company's ability to continue as a going concern. With the third-quarter filing still to come, profitability, Liquidity and a pending merger are the main issues investors may follow. Figures below come from that filing, and market data was not verified.

Latest Company Context

DSS reports four Business lines: product packaging through Premier Packaging, biotechnology, commercial lending through American Pacific Financial, and securities and Investment management, which includes a real estate investment trust. Packaging remains the main revenue source, with printed products contributing about $3.26 million of second-quarter revenue. Total revenue was $3.60 million, down from $5.29 million a year earlier, and six-month revenue was $7.93 million versus $10.24 million.

Cost of revenue exceeded revenue in the quarter, implying a negative gross Margin of roughly 25 percent by our calculation from the reported figures. Six-month net loss was $11.26 million. Cash stood at $4.07 million at June 30, down from $6.21 million at December 31, 2025, with marketable securities of $2.81 million. The REIT and lending businesses add complexity, because investment gains or losses can move reported results independently of operating trends in packaging.

Key Business and index Drivers

The filing identifies negative Working Capital of about $39.9 million, which is central to the going-concern disclosure. Corporate actions could also alter the structure. A $2.45 million Convertible Bond in True Partners, received on March 27, 2026, was converted on April 29 into about 190.7 million shares, leaving DSS with roughly 45 percent and accounting for the stake under the Equity method.

Separately, a merger with Dr Ashleys is pending regulatory approval, and the company said the closing date was uncertain as of August 14, 2026, though it has pointed to the fourth quarter. Shares outstanding rose to 10,042,518 at June 30 from 9,092,518 at year-end 2025, which may matter for per-share results. These are company disclosures, not forecasts. Management also holds marketable securities, and fluctuations in their value could influence reported Earnings in any period. Investors may also consider how equity-method accounting for True Partners could reshape the income statement going forward.

What Investors Should Watch

The next 10-Q, which would cover the quarter ended September 30, 2026, could show whether packaging revenue stabilizes and whether the negative gross margin narrows. Investors may watch cash against the $4.07 million reported in June, any financing or asset sales used to address working capital, and updated going-concern language. Progress on regulatory approval for the Dr Ashleys merger may also matter, as would any change in how True Partners or the biotechnology and lending units contribute to results.

Further share issuance could affect dilution. We did not locate analyst estimates or verified current market data for the stock, so no price or valuation comparison is offered here. Disclosure about the timing of any filing, including whether the company files on schedule, could also be informative. Sector conditions in packaging, commercial lending and biotechnology may affect each unit differently.

Shrinking Revenue, Unresolved Merger

DSS presents a profitability picture defined by shrinking revenue, a negative gross margin and a disclosed going-concern doubt, alongside structural changes that remain unresolved. The coming filing could clarify liquidity and merger timing. Because results depend on several small, varied business lines and on capital-raising decisions, investors may prefer to rely on the company's filings. No index membership was verified for DSS.